California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals
This page contains a discussion of determining the number of primaries. You can review this page in sequence or you can click one of the following links and jump directly to Site, Histology, Timing, or Laterality.
Non-malignant CNS tumors are different primaries at the subsite level.
Meningioma of cervical spine dura (C70.1) and separate meningioma overlying the occipital lobe (C70.0, cerebral meninges). Count and abstract as 2 separate primary tumors.
The exception is when one of the primaries has an NOS site code (C__.9), and the other primary is a specific subsite within the same rubic. Meninges, NOS (C70.9) with spinal meninges (C70.1) or cerebral meninges (C70.0). Count as a single primary and code to the specific subsite.
Refer to the Histology Groups Table below, using the rules in priority order:
Histologic Group |
ICD-O-3 Histology Code |
Choroid plexus neoplasms |
9390/0, 9390/1 |
Ependymomas |
9383, 9394, 9444 |
Neuronal and neuronal-glial neoplasms |
9384, 9412, 9413, 9442, 9505/1, 9506 |
Neurofibromas |
9540/0, 9540/1, 9541, 9550, 9560/0 |
Neurinomatosis |
9560/1 |
Neurothekeoma |
9562 |
Neuroma |
9570 |
Perineuroma, NOS |
9571/0 |
If all histologies are in the same histologic grouping or row in the table, then the histology is the same. Histologies that are in the same groupings are a progression, differentiation or subtype of a single histologic category.
A subependymal giant cell astrocytoma (9384/1) of the cerebrum (C71.0) and a gliofibroma (9442/1) of the Island of Reil (C71.0), count as a single primary.*
A ganglioglioma (9505/1) of the cerebellum (C71.6) and a neurocytoma (9506/1) of the cerebellopontine angle (C71.6), count as a single primary.*
*Note: If one histology is an NOS and the other is more specific, code the specific histology. If both histologies are NOS or both are specific, code the histology that was diagnosed first.
Clear cell meningioma (9538/1) of the cerebral meninges and a separate transitional meningioma (9537/0) in another part of the same hemisphere, count as a single primary.
If a non-malignant tumor of the same histology and same site as an earlier one is subsequently diagnosed at any time, it is considered to be the same primary.
Beginning with malignant and benign/borderline CNS tumors diagnosed January 1, 2004 forward, the following sites require a laterality code of 1- 5 , or 9:
Laterality is used to determine if multiple non-malignant CNS tumors are counted as multiple primary tumors.
B = Benign/borderline tumor
M = Malignant tumor
Same Histology *unless stated to be metastatic or recurrent |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tumor |
Timing (months) |
Same Site |
Different Site |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1st |
2nd |
Same side |
Other side |
Unkn side |
Same side |
Other side |
Unkn side |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
M |
M |
< 2 |
1 |
1 |
1 |
2* |
2* |
2* |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
M |
M |
2 + |
2* |
2* |
2* |
2* |
2* |
2* |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
M |
B |
NA |
2 |
2 |
2 |
2 |
2 |
2 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Different Histology **unless one histology is a specific subtype of the other |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tumor |
Timing (months) |
Same Site |
Different Site |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1st |
2nd |
Same side |
Other side |
Unkn side |
Same side |
Other side |
Unkn side |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
M |
M |
< 2 |
2** |
2** |
2** |
2 |
2 |
2 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
M |
M |
2 + |
2 |
2 |
2 |
2 |
2 |
2 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
M |
B |
NA |
2 |
2 |
2 |
2 |
2 |
2 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B = Benign/borderline tumor
M = Malignant tumor